Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 7:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 33,180 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: HIV Infections
Interventions: Sub C gp140 Vaccine, MF59C.1 Adjuvant, Sodium chloride; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Bovine Milk Oligosaccharide, Placebo Glucose Polymer; Dietary Supplement
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 40 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Davis, California

Conditions: Healthy Subjects
Interventions: HTC-867, Placebo; Drug · Other
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Volunteers
Interventions: OLT maneuver, Sham OLT; Other
Lead sponsor: Kansas City University of Medicine and Biosciences; Other
Eligibility: 20 Years to 40 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Traumatic Brain Injury (TBI), Hazardous and Harmful Alcohol Use
Interventions: Medical Management Counseling, Topiramate, Placebo; Behavioral · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Lupus Nephritis
Interventions: zetomipzomib, placebo; Drug
Lead sponsor: Kezar Life Sciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Lake Charles, Louisiana • East Providence, Rhode Island • Colleyville, Texas + 1 more

Conditions: HIV Infection
Interventions: DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to FDC DOR/ISL; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 28
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 24 more

Conditions: Cannabis Dependence
Interventions: Behavioral Intervention; Behavioral
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Glen Oaks, New York • Manhasset, New York

Conditions: Pain, Osteoarthritis, Knee
Interventions: Transdermal Ketoprofen Patch with CHADD, Placebo transdermal patch; Drug
Lead sponsor: ZARS Pharma Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 5
States / cities: Buena Park, California • Washington D.C., District of Columbia • Daytona Beach, Florida + 2 more

Conditions: Agitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
Interventions: BXCL501, Matching Placebo; Drug
Lead sponsor: BioXcel Therapeutics Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 24
States / cities: Bellflower, California • Cerritos, California • Culver City, California + 19 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, TAK-875, Sitagliptin, TAK-875 and Sitagliptin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 80
States / cities: Birmingham, Alabama • Brimingham, Alabama • Chandler, Arizona + 77 more

Conditions: Parkinson Disease
Interventions: THN102 Dosage A, THN102 Dosage B, THN102 Dosage C; Drug
Lead sponsor: Theranexus; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Kansas City, Kansas • Boston, Massachusetts • Houston, Texas

Conditions: Bipolar Disorder
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 41
States / cities: Birmingham, Alabama • Anaheim, California • Glendale, California + 38 more

Conditions: Smoking
Interventions: Kava, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 21 Years to 99 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Metastatic Renal Cell Carcinoma
Interventions: RAD001, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 31
States / cities: Fayetteville, Arkansas • Duarte, California • Sacramento, California + 27 more

Conditions: Laryngeal Diseases, Chronic Laryngeal Neuropathy
Interventions: Amitriptyline, Placebo; Drug · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 64 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Schizophrenia
Interventions: Paliperidone ER, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 10
States / cities: Cerritos, California • Fountain Valley, California • San Diego, California + 7 more

Conditions: Hip Fracture, Frailty, Sarcopenia
Interventions: Testosterone, Placebo gel, Supervised exercise training, Home exercise program, Health Education Modules; Drug · Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 65 Years and older · Female only
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 8
States / cities: Aurora, Colorado • Farmington, Connecticut • Baltimore, Maryland + 5 more

Conditions: Atopic Dermatitis, Eczema
Interventions: Lebrikizumab, Placebo, Topical Corticosteroid (TCS); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 21
States / cities: Birmingham, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 18 more

Conditions: Obesity
Interventions: Topiramate, Phentermine, Placebo; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Orange, California

Conditions: Arthritis, Rheumatoid
Interventions: Placebo + methotrexate (MTX) (Group 1), Ustekinumab + MTX (Group 2), Ustekinumab + MTX (Group 3), CNTO 1959 + MTX (Group 4), CNTO 1959 + MTX (Group 5); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Palm Harbor, Florida • Rock Island, Illinois • St Louis, Missouri

Conditions: Essential Hypertension, Older Adults
Interventions: chlorthalidone, Placebo; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 60 Years to 85 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Solid Tumor
Interventions: 7HP349 Single Ascending Dose, 7HP349 Multiple Ascending Dose, Placebo Single Ascending Dose, Placebo Multiple Ascending Dose, 7HP349 Food Effect; Drug
Lead sponsor: 7 Hills Pharma, LLC; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Premenstrual Syndrome, Women Health
Interventions: Shatavari Root Extract, Placebo Capsule; Dietary Supplement · Other
Lead sponsor: SF Research Institute, Inc.; Network
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)

Bovine Milk Oligosaccharide Study

Study Evaluating HTC-867 in Healthy Young and Elderly Subjects

Effect of Osteopathic Lymphatic Treatment on Plasma Volume, Protein Concentration and Albumin Concentration.

Topiramate Treatment of Hazardous and Harmful Alcohol Use in Veterans With TBI

A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)

Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine

Transdermal Ketoprofen to Treat Mild to Moderate Osteoarthritis (OA) Pain of the Knee

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)

Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus

Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness

Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder

Reducing Tobacco-associated Lung Cancer Risk: A Randomized Clinical Trial of AB-free Kava

RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib

Trial of the Treatment of Chronic Laryngitis With Amitryptiline

A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients

Starting a Testosterone and Exercise Program After Hip Injury

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery

A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy

Effects of Antihypertensive Drug Treatment on Brain Blood Flow, Cognition, and Regulation of Nervous System in Older Adults With Hypertension.

A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects

Efficacy and Safety of Shatavari Root Extract for Premenstrual Syndrome in Women